GWI
9.9.2021 06:03:06 CEST | Business Wire | Press release
GWI, the leading target audience insight company, today launches its brand-new platform that challenges the status quo in market research. The multi-million dollar investment into the new platform provides access to transformational insights, in a meaningful and visual way. Arming employees with one, consistent in-depth view of their global or local audience, the new capabilities power strategic decisions and enable deep understanding of diverse and evolving audiences.
The new platform makes it easy to be an expert on your audience with smart tools that make it simple to explore available datasets. Users are now able to rapidly access deep insights, answering the questions that matter most to make key business decisions based on facts they can trust. It aids businesses to be truly data-driven by putting accessible insights and bespoke dashboards into the hands of everyone across the organization - from decision makers in the C-suite to data analysts, researchers and marketers.
Tom Smith, CEO and Founder at GWI comments, “The new platform enables a new dawn for the future of marketing research, ensuring it is suited for today's environment which consists of rapid change of pace for business and consumers. Our data shows that 72%* of professionals globally agree that being able to adapt quickly is critical to their company’s long term success. Yet, the traditional market research industry has utterly failed the needs of its customers in today's global marketplace - a world where almost 5 billion people are permanently connected online. Uncovering really transformative insight isn’t easy, nor is it always ‘on time’. Traditional research often takes several months, and can be delayed throughout the process. Despite heavy investment, the insights can therefore quickly become outdated, whilst putting market research out of reach for nearly every single organisation.
“With our new platform combined with our tried and tested methodology, you can secure insights and answers in an instant versus a drawn out process, at a fraction of the traditional market research cost. At the same time, you can ensure organizational alignment, meaning everyone is working from a single source of truth - to tell the same story, inform the decisions that matter and deliver impactful results.”
The intuitive new platform provides access to the world’s largest harmonized ongoing study on digital consumers, representing 2 billion people globally. Users of the flagship survey, GWI Core, alone can gather insights from over 40,000 data points, from over 800,000 interviews. The new platform will foster smarter business decisions and outcomes using hyper-targeted insights into any consumer group, in local and global markets.
To learn more about the new platform including new features and capabilities or to book a demo please visit here .
ENDS
About GWI
GWI is the leading supplier of target audience insight to the global marketing industry.
Trusted by the world’s biggest brands, media organizations, and agencies on a daily basis to get closer to their audiences, the company’s flagship survey represents over 2 billion people globally. Using the subscription-based platform, clients like Twitter, Google, Spotify, WPP, IPG, and Omnicom Group gather in-depth insights into behaviors, attitudes, and interests in seconds through a combination of survey data and analytics.
Among a range of leading data products available alongside its flagship survey are:
- GWI USA is a deep dive into the habits, behaviors and attitudes of 240m internet users in the USA.
- GWI Gaming delves into the actions and attitudes of gamers across 15 markets.
- GWI Sports investigates sports fandom and participation across 15 markets.
- GWI Kids gets to the heart of how kids actually think, so you can be sure to kid-proof your ideas and concepts from here on.
- GWI Work gives a detailed view of the lives of business professionals across 10 markets.
- GWI Zeitgeist, included with our core survey, is fielded monthly and zeroes in on the stuff that matters. It’s topical, timely, and relevant.
Those looking for even more bespoke research solutions can enrich GWI data with a range of services like hyper-targeted custom surveys, brand trackers, and recontact studies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005955/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
